𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Innovative output and firm size in the pharmaceutical industry

✍ Scribed by Samuel B. Graves; Nan S. Langowitz


Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
814 KB
Volume
27
Category
Article
ISSN
0925-5273

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


The relative impact of actual and potent
✍ Karel Cool; Lars-Hendrik RΓΆller; Benoit Leleux πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 3 views

This paper estimates the effects of actual and potential rivalry on profitability of firms in the U.S. pharmaceutical industry during the 20-year period 1963-82. The results show that during the 1960s actual rivalry among the sampled firms did not materially affect firm profitability, but that durin

Strong ties, Substantive Embeddedness an
✍ Philip R. Tomlinson πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 161 KB

Recent work on small and medium enterprises (SMEs) and networks has emphasised the importance of external ties in enhancing firms' innovative performance. Drawing upon survey data from 360 SMEs, this paper explores differences in the strength of UK SMEs' collaborative ties-in a range of activities-w

Product innovation, product–market compe
✍ Peter W. Roberts πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

Increasingly, strategy scholars are exploring the relationships between innovation, competition, and the persistence of superior profits. Sustained high profitability may result when a firm repeatedly introduces valuable innovations that service previously unmet consumer demands. While the returns t

Epidemiology in the pharmaceutical indus
✍ Lewis H Roht; Lauren Shinaberry; Lucy Maybury; Irene Liao; Elinor Riley; Elizabe πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 149 KB πŸ‘ 1 views

A survey assessing the practice of epidemiology in the pharmaceutical industry was sent to all member companies and research affiliates of the Pharmaceutical Research and Manufacturers of America (PhRMA) and to six non-member companies. Eighty-three companies were surveyed. Screening questions estab